Although several IL-1β–targeted therapies, such as anakinra, canakinumab, and rilonacept, have shown efficacy in various neuroinflammatory diseases, no clinical trials in PD or other neurodegenerative disorders have been reported, mainly due to poor blood–brain barrier (BBB) permeability and limited therapeutic efficacy [168]. Here, IL1B is linked to Parkinson disease.